HOXB13 in cancer development: molecular mechanisms and clinical implications.
10.1007/s11684-024-1119-x
- Author:
Jian ZHANG
1
;
Ying Ju LI
2
;
Bo PENG
3
;
Xuna YANG
4
;
Miao CHEN
5
;
Yongxing LI
6
;
Hengbin GAO
7
;
Haitao LI
8
;
Ji ZHENG
9
Author Information
1. Department of Otolaryngology & Head and Neck Surgery, General Hospital of Xinjiang Military Command, Urumqi, 830000, China.
2. State Key Laboratory of Herbage Improvement and Grassland Agro-ecosystems; College of Pastoral Agriculture Science and Technology, Lanzhou University, Lanzhou, 730020, China.
3. State Key Laboratory of Molecular Oncology, Beijing Frontier Research Center for Biological Structure, School of Basic Medical Sciences, Tsinghua University, Beijing, 100084, China.
4. Tai'an Maternal and Child Health Care Hospital, Tai'an, 271000, China.
5. Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi, 830000, China.
6. Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, 400037, China.
7. Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Perth, WA, 6009, Australia. hengbin.gao@uwa.edu.
8. State Key Laboratory of Molecular Oncology, Beijing Frontier Research Center for Biological Structure, School of Basic Medical Sciences, Tsinghua University, Beijing, 100084, China. lht@tsinghua.edu.cn.
9. Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, 400037, China. jizheng023@aliyun.com.
- Publication Type:Review
- Keywords:
HOXB13;
SNPs;
carcinogenesis;
clinical treatment;
epigenetic regulation
- MeSH:
Humans;
Neoplasms/metabolism*;
Homeodomain Proteins/metabolism*;
Carcinogenesis/genetics*;
Mutation;
Gene Expression Regulation, Neoplastic;
Molecular Targeted Therapy;
Drug Resistance, Neoplasm/genetics*
- From:
Frontiers of Medicine
2025;19(3):439-455
- CountryChina
- Language:English
-
Abstract:
The transcription factor HOXB13 plays crucial roles in cancer development. HOXB13 is abnormally expressed in most cancers, which makes it a valuable therapeutic target for cancer therapy. The level of HOXB13 differs significantly between healthy and cancer tissues, which indicates that the level of HOXB13 is closely related to carcinogenesis. The regulatory network mediated by HOXB13 in cancer proliferation, metastasis, and invasion has been systematically investigated. Moreover, HOXB13 variants play distinct roles in different cancers and populations. By understanding the molecular mechanisms and mutation features of HOXB13, we provide a comprehensive overview of carcinogenesis networks dependent on HOXB13. Finally, we discuss advancements in anticancer therapy targeting HOXB13 and the roles of HOXB13 in drug resistance to molecular-targeted therapies, which serves as a foundation for developing HOXB13-targeted drugs for clinical diagnosis and cancer therapies.
